Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Paclitaxel - Beigene/Celgene Corporation

Next Previous
Drug Profile

Paclitaxel - Beigene/Celgene Corporation

Alternative Names: ABI-007; ABRAXANE; Abraxane; ABRAXUS; Albumin-bound paclitaxel - Celgene Corporation; Coraxane; Coroxane; Nab-Paclitaxel; Systemic nanoparticle albumin-bound paclitaxel

Latest Information Update: 08 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abraxis BioScience
  • Developer Abraxis BioScience; AstraZeneca; Australian and New Zealand Urogenital and Prostate Cancer Group; BeiGene; Big Ten Cancer Research Consortium; Biotoscana; Cambridge University Hospitals; Cancer Research UK; Celgene Corporation; Columbia University; Eli Lilly and Company; Emory University; Fondazione Sandro Pitigliani; Genentech; Institut fuer Frauengesundheit; M. D. Anderson Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); NCIC Clinical Trials Group; New York University School of Medicine; Oncosur; PrECOG; Southeastern Gynecologic Oncology; Taiho Pharmaceutical; University of California, Davis; University of Iowa; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer
  • Registered Squamous cell cancer
  • Phase II Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Head and neck cancer; HER2 negative breast cancer; Malignant melanoma; Oesophageal cancer; Small cell lung cancer; Urogenital cancer
  • Phase I/II Multiple myeloma; Solid tumours
  • No development reported Bladder cancer; Ovarian cancer; Prostate cancer
  • Discontinued Coronary artery restenosis; Peripheral arterial disorders; Vascular restenosis

Most Recent Events

  • 18 Jan 2024 Efficacy and adverse event data from the phase II ALPACA trial in Pancreatic cancer presented at the 2024 Gastrointestinal Cancers Symposium (ASCO-GCS-2024)
  • 15 Dec 2023 ORIC Pharmaceuticals terminates a phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (PO) due to IND withdrawal (NCT03928314)
  • 17 Aug 2023 Celgene completes the phase II abound2L+ trial in Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater, Combination therapy, Monotherapy) in USA, Spain, Canada, France, Germany, Italy, and United Kingdom (IV) (NCT02250326) (EudraCT2014-001105-41)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top